Index | - |
P/E | - |
EPS (ttm) | - |
Insider Own | 56.63% |
Shs Outstand | 33.43M |
Perf Week | -5.93% |
Market Cap | 768.89M |
Forward P/E | - |
EPS next Y | -2.20 |
Insider Trans | 272.01% |
Shs Float | 14.50M |
Perf Month | 1.72% |
Enterprise Value | 867.57M |
PEG | - |
EPS next Q | -0.50 |
Inst Own | 24.00% |
| |
Perf Quarter | - |
Income | - |
P/S | - |
EPS this Y | 89.49% |
Inst Trans | 8.10% |
| |
Perf Half Y | - |
Sales | - |
P/B | - |
EPS next Y | -16.52% |
ROA | - |
| |
Perf YTD | -12.88% |
Book/sh | -2.96 |
P/C | 7.16 |
EPS next 5Y | 48.42% |
ROE | - |
52W High | 32.44 -29.10% |
Perf Year | - |
Cash/sh | 3.21 |
P/FCF | - |
EPS past 3/5Y | -69.04% - |
ROIC | - |
52W Low | 20.15 14.14% |
Perf 3Y | - |
Dividend Est. | - |
EV/EBITDA | - |
Sales past 3/5Y | - - |
Gross Margin | - |
Volatility | 6.23% 7.67% |
Perf 5Y | - |
Dividend TTM | - |
EV/Sales | - |
EPS Y/Y TTM | - |
Oper. Margin | - |
ATR (14) | 1.69 |
Perf 10Y | - |
Dividend Ex-Date | - |
Quick Ratio | 12.67 |
Sales Y/Y TTM | - |
Profit Margin | - |
RSI (14) | 43.48 |
| |
Dividend Gr. 3/5Y | - - |
Current Ratio | 12.67 |
EPS Q/Q | - |
SMA20 | -2.35% |
Beta | - |
| |
Payout | - |
Debt/Eq | 0.01 |
Sales Q/Q | - |
SMA50 | -9.94% |
Rel Volume | 0.14 |
Prev Close | 23.65 |
Employees | 65 |
LT Debt/Eq | 0.01 |
| |
SMA200 | -10.59% |
Avg Volume | 131.21K |
Price | 23.00 |
IPO | Feb 06, 2026 |
Option/Short | No / Yes |
| |
Trades | |
Volume | 19,144 |
Change | -2.75% |
|
 |
|
|
|
| |
| Date |
Action |
Analyst |
Rating Change |
Price Target Change |
| Mar-10-26 | Initiated |
H.C. Wainwright |
Buy |
$37 |
| Mar-03-26 | Initiated |
Stifel |
Buy |
$42 |
| Mar-03-26 | Initiated |
Leerink Partners |
Outperform |
$42 |
| Mar-03-26 | Initiated |
Jefferies |
Buy |
$62 |
| Mar-03-26 | Initiated |
Citigroup |
Buy |
$42 |
|
|
|
Mar-26-26 04:05PM
|
|
|
Mar-09-26 08:00AM
|
|
|
Mar-04-26 08:00AM
|
|
|
Mar-03-26 09:33AM
|
|
|
08:00AM
|
|
| 08:40AM |
Loading… |
|
Feb-16-26 08:40AM
|
|
|
Feb-09-26 04:05PM
|
|
|
|
|
|
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA. | |
|
|
|
| |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | Director | Feb 09 '26 | Buy | 16.00 | 3,690,000 | 59,040,000 | 5,966,439 | Feb 11 05:15 PM | | Behbahani Ali | Director | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Florence Anthony A. Jr. | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | BASKETT FOREST | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | New Enterprise Associates 17, | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Yang Rick | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Makhzoumi Mohamad | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | SANDELL SCOTT D | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Chang Carmen | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Walker Paul Edward | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Mathers Edward T | 10% Owner | Feb 09 '26 | Buy | 16.00 | 937,500 | 15,000,000 | 6,035,038 | Feb 11 04:30 PM | | Pardo Geoffrey B | Director | Feb 09 '26 | Buy | 16.00 | 312,500 | 5,000,000 | 2,187,513 | Feb 11 04:09 PM | | Khan Bilal Arshad | Director | Feb 09 '26 | Buy | 16.00 | 115,000 | 1,840,000 | 251,427 | Feb 11 04:07 PM | | Khan Bilal Arshad | Director | Feb 09 '26 | Buy | 16.00 | 20,000 | 320,000 | 25,450 | Feb 11 04:07 PM | | Nielsen Kirk G. | Director | Feb 09 '26 | Buy | 16.00 | 165,000 | 2,640,000 | 3,310,619 | Feb 10 06:09 PM | | Vensana Capital I GP, LLC | 10% Owner | Feb 09 '26 | Buy | 16.00 | 165,000 | 2,640,000 | 3,310,619 | Feb 10 06:08 PM |
|
|
